The White House COVID-19 Response Team and public health officials hold a briefing as advisers to the U.S. Centers for Disease Control and Prevention prepare to decide on the use of Moderna's COVID vaccine for children and adolescents aged 6 to 17, after months of delay in that age group due to safety concerns.